Hepmarc: A 96 week randomised controlled feasibility trial of add-on maraviroc in people with HIV and non-alcoholic fatty liver disease

OBJECTIVES: Maraviroc may reduce hepatic inflammation in people with HIV and non-alcoholic fatty liver disease (HIV-NAFLD) through CCR5-receptor antagonism, which warrants further exploration. METHODS: We performed an open-label 96-week randomised-controlled feasibility trial of maraviroc plus optim...

Descripción completa

Detalles Bibliográficos
Autores principales: Bradshaw, Daniel, Abramowicz, Iga, Bremner, Stephen, Verma, Sumita, Gilleece, Yvonne, Kirk, Sarah, Nelson, Mark, Housman, Rosalie, Miras, Helena, Orkin, Chloe, Fox, Ashini, Curnock, Michael, Jennings, Louise, Gompels, Mark, Clarke, Emily, Robinson, Rachel, Lambert, Pauline, Chadwick, David, Perry, Nicky
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348519/
https://www.ncbi.nlm.nih.gov/pubmed/37450478
http://dx.doi.org/10.1371/journal.pone.0288598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348519/
https://www.ncbi.nlm.nih.gov/pubmed/37450478
http://dx.doi.org/10.1371/journal.pone.0288598

Ejemplares similares